hotspot -WSS

hotspot

author：explore 2025-09-30 12:21:44 - browse：49

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Eight reasons why you should get an updated Covid vaccine

entertainment

WSS

Humana CEO Bruce Broussard to step down in 2024

Takeaways from AdvaMed, the largest medical devices conference

The system is set up to fail children with medical complexity

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Nick Jonas talks about managing diabetes along with his career

Eight reasons why you should get an updated Covid vaccine

explore

hotspot

hotspot

Continuity nursing helped my family in our darkest PICU moments

STAT Readout Newsletter: Today in biotech, life science news

After affirmative action ruling, medical educators look to 'holistic review'

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

The system is set up to fail children with medical complexity

Cancer drug shortages should be causing more outrage

How clinical AI models' predictive power can degrade over time

Malaria cases in Florida and Texas: Here’s what you need to know

Study: Why relieving medical debt did not improve financial outcomes

focus

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

Life sciences deals on track to hit lowest point since 2017

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Akero's treatment for NASH falls short in cirrhosis study

Takeaways from AdvaMed, the largest medical devices conference

Life sciences deals on track to hit lowest point since 2017

leisure time

entertainment

knowledge

entertainment